|
Includes all of these presentations from this session:
| # |
Presentation |
Speaker |
| 1 |
Can LG glandular dysplasia give rise directly to invasive Ca? |
V. Villanacci (Brescia) |
| 2 |
Aneuploidy as a predictor of dysplasia ? Is it really practical? |
X. Sagaert (Leuven) |
| 3 |
Tumor markers for use in personalized medecin? |
P.E. Swanson (Seattle) |
| 4 |
Is P53 immunoreactive glandular dysplasia at higher risk than nonimmunoreactive mucosa for developing progression? |
H.D. Appelman (Ann Arbor) |
| 5 |
Does racemase immunoreactivity predict increased risk of carcinoma |
R.H. Riddell (Toronto) |
| 6 |
Do lectins have a role in the progression to adenocarcinoma |
P.E. Swanson (Seattle) |
| 7 |
Is there a standardized grading system for tumor regression in Squamous and in Adenocarcinoma? |
X. Sagaert (Leuven) |
| 8 |
Mutational spectra of Barrett?s esophagus and adenocarcinoma |
I. Parker (Cape Town) |
| 9 |
Significance of post neo-adjuvant therapy residual endocrine cells and mucin pools |
D. Jain (New Haven, CT) |
| 10 |
Are there molecular markers of patients presenting complete response to neoadjuvant chemo-radiotherapy? |
L.F. Ribeiro Pinto (Rio de Janeiro) |
| 11 |
Can LG squamous dysplasia/IEN give rise directly to invasive Ca? |
V. Villanacci (Brescia) |
| 12 |
Are HPV and nonHPV squamour dysplasias/IEN at the same risk of subsequent invasion? |
R.K. Yantiss (New York) |
|
